Estudo randomizado | CoronaVac mostrou eficácia de 83,5% na prevenção de infecção sintomática por SARS-CoV-2.
9 Jul, 2021 | 16:13hComentário convidado: CoronaVac: more data for regulators and policy makers
Comentário no Twitter
NEW—Interim analysis from phase 3 trial suggests efficacy of 2 doses of #CoronaVac is 83.5% against symptomatic #COVID19. More research is needed to confirm efficacy in the long term, in a more diverse group, and against emerging #variants of concern.
🔗 https://t.co/TN5b6wwclc pic.twitter.com/4zOvJFIIOH
— The Lancet (@TheLancet) July 8, 2021